Shares of Emcure Pharmaceuticals faced downward pressure on Monday following a social media controversy involving Namita Thapar, the company’s Executive Director. Despite a general market upswing, the stock declined, reflecting investor unease over the ongoing online backlash.
As of the latest update, Emcure Pharma shares were down by 2.64% at Rs 1,628.
The controversy originated from a video shared by Namita Thapar in late March. In the video, she discussed the health benefits of Namaz, portraying it as a holistic exercise regimen. Emphasizing its positive effects on digestion, flexibility, and mental well-being, Thapar highlighted the meditative aspect of Namaz that could contribute to mental health. She also mentioned the digestive advantages and calming influence of the Vajrasana posture within the practice.
Although the video gained significant traction online, it also drew criticism and trolling on social platforms, sparking a wider debate. Responding to the backlash on a platform called X, Thapar clarified that she had previously shared similar content related to Hindu practices.
While the overall market sentiment remained positive, Emcure Pharma’s stock moved in the opposite direction, indicating investor vigilance towards unfolding events. The stock decline underscores the potential impact of reputational concerns on short-term market sentiment.
This scenario underscores the swift influence of social media reactions on market dynamics, particularly when senior corporate figures are involved.